Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
67.50    -0.50 (-0.74%)
Bid:
67.40
Ask:
67.60
Spread: 0.20 (0.297%)
Market Cap: £596.31m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Director/PDMR Shareholding, SAYE scheme

7 Sep 2022 16:33

RNS Number : 6669Y
IP Group PLC
07 September 2022
 

FOR RELEASE ON

07 September 2022

 

IP Group plc - SAYE Scheme; PDMR shareholding

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces the following in connection with its employee share schemes.

 

 

SAVE AS YOU EARN ("SAYE") SHARESAVE PLAN

 

IP Group has granted options over the Company's ordinary shares of 2p each ("Shares"), under its SAYE Sharesave Plan to persons discharging managerial responsibilities ("PDMRs") of the Company as detailed below.

 

 Name

Plan duration

Number of options granted

Greg Smith

3 years

27,692

David Baynes

3 years

27,692

Angela Leach

3 years

11,076

Lisa Patel

3 years

22,153

Mark Reilly

3 years

16,615

Douglas Moray Wright

3 years

27,692

Anthony York

3 years

19,384

 

In addition to the above, options over a total of 439,796 Shares were granted to certain other employees of the Group under the Sharesave Plan.

 

All of the above SAYE options have been granted on 07 September 2022 at an exercise price of 65.0 pence per share, with the SAYE contracts commencing on 01 November 2022. The exercise price was set in accordance with HM Revenue & Customs rules for Sharesave plans.

Permitted exercise periods are for a period of six months from the end of the plan period, ordinarily 01 November 2025.

 

Shares in issue

At the date of this announcement, the Company continues to have 1,063,033,287 Shares in issue and 28,607,622 Shares held in treasury.

The following information is being disclosed pursuant to the requirements of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

 

 

 

SAYE Sharesave Plan

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name(s)

Greg Smith

David Baynes

Angela Leach

Lisa Patel

Mark Reilly

Douglas Moray Wright

Anthony York

2

Reason for the notification

a)

Position/status

Executive Director Chief Executive Officer

Executive Director Chief Financial and Operating OfficerPDMR Group General Counsel

PDMR Partner, Life Sciences

PDMR Managing Partner, Technology

PDMR CEO Parkwalk

PDMR Group People Director

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IP Group plc

b)

Legal Entity Identifier

213800HG22UM138WFG43

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 2p each in IP Group plc

 ISIN: GB00B128J450

b)

Nature of the transaction

Conditional award of Shares under the IP Group plc SAYE Sharesave Plan

c)

Currency

GBP

d)

Price(s) and volume(s)

Name(s)

 

Price(s)

Volume(s)

Greg Smith

65.0p

27,692

David Baynes

65.0p

27,692

Angela Leach

65.0p

11,076

Lisa Patel

65.0p

22,153

Mark Reilly

65.0p

16,615

Douglas Moray Wright

65.0p

27,692

Anthony York

65.0p

19,384

e)

Aggregated information

-Aggregated volume

 

- Price

- Aggregated total

 

Aggregated Number of Shares conditionally awarded under the SAYE Sharesave Plan to PDMRs on 07 September 2022: 152,304

Price: 65.0p

f)

Date of the transaction

07 September 2022

g)

Place of the transaction

Outside a trading venue

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7967 312125

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUBUVRUKUKRAR
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.